FN2 Earnings Intelligence
Quest Diagnostics Incorporated financials (quarterly)
Quest Diagnostics Incorporated (DGX) Key Stats (quarterly) derived from persisted SEC financial facts.
Key Stats
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 | 9/30/2026 est. | 12/30/2026 est. |
|---|---|---|---|---|---|---|---|
| Market Cap | - | - | - | - | - | - | - |
| - Cash | $188 | $319 | $432 | $393 | $626 | - | - |
| + Debt | - | - | - | - | - | - | - |
| Enterprise Value | - | - | - | - | - | - | - |
| Revenue | $2,652 | $2,761 | $2,816 | $2,895 | $3,043 | $3,032.2 | $2,998 |
| % Growth | - | - | - | - | - | 7.7% | - |
| Gross Profit | $863 | $943 | $949 | $942 | $1,027 | - | - |
| % Margin | 32.5% | 34.2% | 33.7% | 32.5% | 33.7% | - | - |
| EBITDA | $486 | $581 | $528 | $546 | $605 | - | - |
| % Margin | 18.3% | 21.0% | 18.8% | 18.9% | 19.9% | - | - |
| Net Income | $220 | $282 | $245 | $252 | $320 | - | - |
| % Margin | 8.3% | 10.2% | 8.7% | 8.7% | 10.5% | - | - |
| Diluted EPS | $1.94 | $2.47 | $2.16 | $2.24 | $2.84 | $2.85 | $2.66 |
| % Growth | - | - | - | - | - | 32.1% | - |
| Operating Cash Flow | $314 | - | - | $278 | - | - | - |
| CapEx | $117 | - | - | $114 | - | - | - |
| Free Cash Flow | $197 | - | - | $164 | - | - | - |
Historical market capitalization is not persisted, so Market Cap and Enterprise Value remain unavailable rather than mixing today's market value into prior periods.
Income Statement
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 | 9/30/2026 est. | 12/30/2026 est. |
|---|---|---|---|---|---|---|---|
| Revenue | $2,652 | $2,761 | $2,816 | $2,895 | $3,043 | $3,032.2 | $2,998 |
| Gross Profit | $863 | $943 | $949 | $942 | $1,027 | - | - |
| EBITDA | $486 | $581 | $528 | $546 | $605 | - | - |
| Net Income | $220 | $282 | $245 | $252 | $320 | - | - |
| Diluted EPS | $1.94 | $2.47 | $2.16 | $2.24 | $2.84 | $2.85 | $2.66 |
Balance Sheet
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 |
|---|---|---|---|---|---|
| Cash & Equivalents | $188 | $319 | $432 | $393 | $626 |
| Short-term Debt | - | - | - | - | - |
| Long-term Debt | $215 | - | - | - | $5,632 |
| Total Debt | - | - | - | - | - |
Cash Flow
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | $314 | - | - | $278 | - |
| Capital Expenditure | $117 | - | - | $114 | - |
| Free Cash Flow | $197 | - | - | $164 | - |
Ratios
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 |
|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - |
| Gross Margin | 32.5% | 34.2% | 33.7% | 32.5% | 33.7% |
| EBITDA Margin | 18.3% | 21.0% | 18.8% | 18.9% | 19.9% |
| Net Margin | 8.3% | 10.2% | 8.7% | 8.7% | 10.5% |
| FCF Margin | 7.4% | - | - | 5.7% | - |
| Diluted EPS Growth | - | - | - | - | - |